The pharmaceutical and biopharmaceutical sector is one among the largest R&D spenders globally. Within the last decade, the R&D expenditure of pharmaceutical and biopharmaceutical companies has risen considerably. This is often expected to guide to an increase within the number of clinical trials conducted globally. Consistent with the Pharmaceutical Research and manufacturers of America (PhRMA), PhRMA members have invested significantly in drug development efforts. Companies within the market are actively looking to support R&D efforts. An extra increase in R&D spending within the coming years will significantly boost drug discovery and development activities, thus driving the demand for clinical test supplies.
Drug discovery and development involve high costs because of the high attrition rate of drug candidates in development. Since R&D for a few rare diseases is extremely challenging and requires a selected group of individuals to conduct a clinical test, drug R&D processes are often at risk of failure.
Covid-19 Impact on Clinical Trial Supplies Market:
In addition, the present Global Market study offers an in depth analysis of the present COVID-19 pandemic impact on the market growth and its influence on the longer term growth of the worldwide Market. The recently published report demonstrates the elevation within the demand for the healthcare sector. The healthcare manufacturers have experienced future also as short term effect which incorporates supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption might be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and makers to the limit. In addition to the present, panic conditions have already spurred the demand for several healthcare products and services which are discussed intimately during this report. Moreover, the impact of this pandemic on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Clinical Trial Supplies Market Segment Overview
By Product and Services segment, Supply and chain management holds the major market share in estimated time period. Also, Globalization of clinical trials and a rise within the number of clinical sites are expected to drive the demand for supply chain management systems by bioscience companies and CROs. Moreover, Adoption of mobile and provide chain management technology is predicted to be the driving factor for segment growth.
By Therapeutic area, Oncology is that the largest segment during this market due to the high and growing number of research studies on cancer therapeutics and therefore the increasing number of companies that specialize in bringing innovative cancer drugs into the market. Considering the high incidence and prevalence of cancer, healthcare systems across the world are specializing in reducing the burden of cancer by adopting innovative diagnostic and therapeutic approaches.
By End-users, the pharmaceutical and biotechnology companies accounted for the most important share of this market in 2020. This share is attributed to the rising R&D efforts by these companies.
Market Analysis, Insights and Forecast – By Product and Services
- Manufacturing
- Storage & Distribution
- Cold Chain Distribution
- Non-cold Chain Distribution
- Supply Chain Management
· Oncology
· CNS and mental disorders
· Cardiovascular diseases
· Digestive disorders
· Infectious diseases
· Metabolic disorders
· Immunology
· Blood disorders
· Other
Market Analysis, Insights and Forecast – By End Users
· Hospitals
· Pharmaceutical & Biotechnology companies
· Contract Research Organisations (CROs)
· Medical Devices Companies
· Other
Clinical Trial Supplies Market Regional Overview
Region-wise, in terms of regions, North America accounted for the biggest share of the clinical trial supplies market, followed by Europe & Asia Pacific. The growing number of registered clinical trials and significant investments in R&D for clinical trials during this region are major factors driving the expansion of the North American market.
Clinical Trial Supplies Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Clinical Trial Supplies Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Clinical Trial Supplies are highlighted below.
· In April 2021, Thermo Fisher announced plans to acquire PPD to enhance its offerings in clinical research services and to support clinical trials
Clinical Trial Supplies Market, Key Players
· Thermo Fisher
· Catalent, Inc.
· Parexel
· Eurofins
· UDG Healthcare
· Piramal Pharma Solutions
· Almac Group
· PCI Pharma Services
· PRA Health Sciences
· Biocair
· Eurofins
· Marken
· Infosys
· Liveo Research
· Capsugel
· SIRO Clinpharm
· KLIFO A/S
· Clinigen
· Ancillare
· N-SIDE
· ADAllen
· Rubicon
· Durbin
· Recipharm
· Seveillar
· Myonex
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Clinical Trial Supplies Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product And Services
- 5.2.1. Manufacturing
- 5.2.2. Storage & Distribution
- 5.2.2.1. Cold Chain Distribution
- 5.2.2.2. Non-cold Chain Distribution
- 5.2.3. Supply Chain Management
- 5.3. Market Analysis, Insights and Forecast – By Therapeutic area
- 5.3.1. Oncology
- 5.3.2. CNS and mental disorders
- 5.3.3. Cardiovascular diseases
- 5.3.4. Digestive disorders
- 5.3.5. Infectious diseases
- 5.3.6. Metabolic disorders
- 5.3.7. Immunology
- 5.3.8. Blood disorders
- 5.3.9. Other
- 5.4. Market Analysis, Insights and Forecast – By End Users
- 5.4.1. Hospitals
- 5.4.2. Pharmaceutical & Biotechnology companies
- 5.4.3. Contract Research Organisations (CROs)
- 5.4.4. Medical Devices Companies
- 5.4.5. Other
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East, and Africa
6. North America Clinical Trial Supplies Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product And Services
- 6.2.1. Manufacturing
- 6.2.2. Storage & Distribution
- 6.2.2.1. Cold Chain Distribution
- 6.2.2.2. Non-cold Chain Distribution
- 6.2.3. Supply Chain Management
- 6.3. Market Analysis, Insights and Forecast – By Therapeutic area
- 6.3.1. Oncology
- 6.3.2. CNS and mental disorders
- 6.3.3. Cardiovascular diseases
- 6.3.4. Digestive disorders
- 6.3.5. Infectious diseases
- 6.3.6. Metabolic disorders
- 6.3.7. Immunology
- 6.3.8. Blood disorders
- 6.3.9. Other
- 6.4. Market Analysis, Insights and Forecast – By End Users
- 6.4.1. Hospitals
- 6.4.2. Pharmaceutical & Biotechnology companies
- 6.4.3. Contract Research Organisations (CROs)
- 6.4.4. Medical Devices Companies
- 6.4.5. Other
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Clinical Trial Supplies Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product And Services
- 7.2.1. Manufacturing
- 7.2.2. Storage & Distribution
- 7.2.2.1. Cold Chain Distribution
- 7.2.2.2. Non-cold Chain Distribution
- 7.2.3. Supply Chain Management
- 7.3. Market Analysis, Insights and Forecast – By Therapeutic area
- 7.3.1. Oncology
- 7.3.2. CNS and mental disorders
- 7.3.3. Cardiovascular diseases
- 7.3.4. Digestive disorders
- 7.3.5. Infectious diseases
- 7.3.6. Metabolic disorders
- 7.3.7. Immunology
- 7.3.8. Blood disorders
- 7.3.9. Other
- 7.4. Market Analysis, Insights and Forecast – By End Users
- 7.4.1. Hospitals
- 7.4.2. Pharmaceutical & Biotechnology companies
- 7.4.3. Contract Research Organisations (CROs)
- 7.4.4. Medical Devices Companies
- 7.4.5. Other
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Clinical Trial Supplies Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product And Services
- 8.2.1. Manufacturing
- 8.2.2. Storage & Distribution
- 8.2.2.1. Cold Chain Distribution
- 8.2.2.2. Non-cold Chain Distribution
- 8.2.3. Supply Chain Management
- 8.3. Market Analysis, Insights and Forecast – By Therapeutic area
- 8.3.1. Oncology
- 8.3.2. CNS and mental disorders
- 8.3.3. Cardiovascular diseases
- 8.3.4. Digestive disorders
- 8.3.5. Infectious diseases
- 8.3.6. Metabolic disorders
- 8.3.7. Immunology
- 8.3.8. Blood disorders
- 8.3.9. Other
- 8.4. Market Analysis, Insights and Forecast – By End Users
- 8.4.1. Hospitals
- 8.4.2. Pharmaceutical & Biotechnology companies
- 8.4.3. Contract Research Organisations (CROs)
- 8.4.4. Medical Devices Companies
- 8.4.5. Other
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East, and Africa Clinical Trial Supplies Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product And Services
- 9.2.1. Manufacturing
- 9.2.2. Storage & Distribution
- 9.2.2.1. Cold Chain Distribution
- 9.2.2.2. Non-cold Chain Distribution
- 9.2.3. Supply Chain Management
- 9.3. Market Analysis, Insights and Forecast – By Therapeutic area
- 9.3.1. Oncology
- 9.3.2. CNS and mental disorders
- 9.3.3. Cardiovascular diseases
- 9.3.4. Digestive disorders
- 9.3.5. Infectious diseases
- 9.3.6. Metabolic disorders
- 9.3.7. Immunology
- 9.3.8. Blood disorders
- 9.3.9. Other
- 9.4. Market Analysis, Insights and Forecast – By End Users
- 9.4.1. Hospitals
- 9.4.2. Pharmaceutical & Biotechnology companies
- 9.4.3. Contract Research Organisations (CROs)
- 9.4.4. Medical Devices Companies
- 9.4.5. Other
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Thermo Fisher
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Catalent, Inc.
- 10.6. Parexel
- 10.7. Eurofins
- 10.8. UDG Healthcare
- 10.9. Piramal Pharma Solutions
- 10.10. Almac Group
- 10.11. PCI Pharma Services
- 10.12. PRA Health Sciences
- 10.13. Biocair
- 10.14. Eurofins
- 10.15. Marken
- 10.16. Infosys
- 10.17. Liveo Research
- 10.18. Capsugel
- 10.19. SIRO Clinpharm
- 10.20. KLIFO A/S
- 10.21. Clinigen
- 10.22. Ancillare
- 10.23. N-SIDE
- 10.24. ADAllen
- 10.25. Rubicon
- 10.26. Durbin
- 10.27. Recipharm
- 10.28. Seveillar
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
